Mending the Broken Heart: A Neprilysin Inhibitor for Heart Failure
详细信息 查看全文
- 作者：Morgan B. Adams ; PharmD ; BCACPAuthor Vitae ; Rodel V. Bobadilla ; NP-C ; FNP-BCAuthor Vitae ; Sarah L. Blandy ; PharmDAuthor Vitae ; Farah R. Kablaoui ; PharmD ; BCPSAuthor Vitae
- 关键词：Entresto ; heart failure ; neprilysin inhibitor ; reduced ejection fraction ; sacubitril/valsartan
- 刊名：The Journal for Nurse Practitioners
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：12
- 期：3
- 页码：e111-e114
- 全文大小：194 K
文摘
- •
Sacubitril/valsartan was recently FDA approved to reduce morbidity and mortality in patients with reduced ejection fraction heart failure
- •
This medication is the first in the class of neprilysin inhibitors
- •
Sacubitril/valsartan could replace angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) as the standard of care in heart failure